StreetInsider.com News Articles

Form 8-K Vistagen Therapeutics, For: Jun 16

Wed, 17 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660927.html

Form 8-K Vistagen Therapeutics, For: Jun 16

Wed, 17 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660927.html

Form 10-K Vistagen Therapeutics, For: Mar 31

Mon, 15 Jun 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26648190.html

Form 10-K Vistagen Therapeutics, For: Mar 31

Mon, 15 Jun 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26648190.html

Form 8-K Vistagen Therapeutics, For: Jun 15

Mon, 15 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260615/26647963.html

Form 8-K Vistagen Therapeutics, For: Jun 15

Mon, 15 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260615/26647963.html

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Received FDA “Study May Proceed” letter under refisolone Investigational New Drug (IND) application to support further clinical development in the U.S. for treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Mon, 15 Jun 2026 16:30:00 -0400

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month

Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026

Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program

Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial

Form 8-K Vistagen Therapeutics, For: Jun 09

Tue, 09 Jun 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260609/26624657.html

Form 8-K Vistagen Therapeutics, For: Jun 09

Tue, 09 Jun 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260609/26624657.html

Vistagen meets ICH safety exposure standards for fasedienol trials

Tue, 09 Jun 2026 08:31:17 -0400

Vistagen (NASDAQ: VTGN) announced that its clinical program for fasedienol nasal spray has achieved minimum patient exposure recommendations under ICH E1 international regulatory standards for drugs intended for long-term treatment of non-life-threatening conditions.

As of May 31, 2026, the company reports over 1,500 subjects received at least one exposure to fasedienol, with over 300 subjects having at least six months of exposure and over 100 subjects with at least 12 months of exposure. These figures represent estimates of subjects who completed visits in fasedienol open-label safety studies.

The exposure numbers include participants from ongoing open-label extensions of Vistagen's PALISADE-3 and PALISADE-4 Phase

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Tue, 09 Jun 2026 08:30:00 -0400

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory standard governing safety database exposure recommendations for drugs intended for long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening conditions1.

As of May 31, 2026,

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Tue, 09 Jun 2026 08:30:00 -0400

As of May 31, 2026,

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Tue, 09 Jun 2026 08:30:00 -0400

As of May 31, 2026,

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Tue, 09 Jun 2026 08:30:00 -0400

As of May 31, 2026,